We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: My Perspective on the High Cost of Cancer Drugs
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > My Perspective on the High Cost of Cancer Drugs
BusinessFinanceSpecialties

My Perspective on the High Cost of Cancer Drugs

Andrew Schorr
Andrew Schorr
Share
5 Min Read
SHARE

cancer drugsDr. Leonard Salz, a renowned GI cancer specialist at Memorial Sloan Kettering Cancer Center in New York, said on the U.S.

cancer drugsDr. Leonard Salz, a renowned GI cancer specialist at Memorial Sloan Kettering Cancer Center in New York, said on the U.S. news program “60 Minutes” the other night that we must—in the U.S.—discuss the high cost of cancer drugs. Dr. Hagop Kantarjian, head of the leukemia department at MD Anderson, whom I know well, agrees as do so many other doctors, patient advocates and patients. Many therapies are now costing over $100,000 a year. And in this age of “chronic cancer,” you might take that medicine for years. Now some experts are saying to really keep the cancer at bay you need to take more than one medicine together. $200,000+ a year for many years?

Just this week we are releasing a roundtable discussion with lymphoma experts and one segment is devoted to the high cost of the newest medicines.

Obviously the expenditure is not sustainable. In my own case, I received six cycles of chemotherapy (and supportive care medicines, too) in 2000 for my chronic lymphocytic leukemia (CLL).  And then I was done. I have had no other CLL medicine since then and, fortunately, that disease remains in remission. Not everyone is so lucky, and they may be candidates—maybe me too in the future—for one of the new anti-CLL pills used alone and in combination. Again, around $100k per year per patient for each medicine.

More Read

Health Care Buzz Today
Diagnostic Reading #33: Five Must-Read Articles from the Past Week
How You’re Going to Pay for Hurricane Irene
Can We Take the Excitement out of the FDA? Agency Could be Turning a Corner
What Is Protected Health Information?

But I haven’t been spared a high cost med even now. I developed a second cancer in 2011, myelofibrosis. I am very grateful there is a pill that has been remarkable in controlling the symptoms of the disease. I take a small white pill every morning and evening and lead a normal life. When I arrange refills, I am delighted to hear that right now I have no co-pay. The cost of the drug to insurance? About $8,000 a month.

At age 64, I am approaching Medicare coverage. Will I have the 20 percent co-pay to shoulder? Maybe so. Is it worth it? Probably. But should prices be that high anyway and to remain high year after year? For example, should prices decline over time as pharma makes its money back and then some? Stockholders are happy, and a growing number of patients—living longer—can afford to live well without going broke.  One problem is a law that makes Medicare pay retail prices. Instead, they should have huge buying power and negotiate lower prices as do government agencies in other countries.

I am not trying to stifle medical innovation by for-profit companies. I am very grateful to Genentech and Roche for Rituxan in 2000 (I received it in a trial so, I believe, at no cost to my providers) and to Incyte for developing Jakafi, the pills that help me to live a full life today. But we have to have a serious ongoing discussion about what is right, moral and sustainable. This must include oncology professionals, government officials, insurance companies, pharma and, most importantly, you and me as patients and care team members.

One other point. In the U.S., many oncology clinics make extra money on dispensing more expensive IV medicines. The doctors get a commission, and some would say this encourages them to use a more expensive medicine—but not necessarily a more effective one—in order to get a higher fee. You, the patient, have no idea. Here we need transparency. We need to be able to trust our doctors not just to treat our cancer effectively and with the least “clinical toxicity” but also with the least “financial toxicity.”

As more people survive cancer and remain on ongoing medicines, the U.S. has to have a fair and open discussion about the cost of cancer medicines. Thanks to various medical journals, leading physicians, patient groups and now the media for bringing attention to this issue. In the U.S. now, one out of every three of us will face some type of cancer.  The high cost of one or more cancer medicines can be a clear a present danger, for some, as worrisome as the cancer itself.

I urge you to comment on this as we need to keep this discussion rolling.

TAGGED:cancerpharma
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026
Flat editorial illustration: The article connects routine occupational health screening with early exposure detection and better
What Routine Workplace Health Monitoring in Medical Environments Actually Prevents
Uncategorized
November 6, 2026
Flat editorial illustration: The article contrasts structured prelicensure education with ongoing, practice-focused development f
Academic vs. Clinical Education: How Teaching Settings Shape Nursing Learners and Outcomes
Uncategorized
November 6, 2026
Flat editorial illustration: Health-editorial illustration of the two-way relationship between substance use and disrupted sleep,
How Sleep Disruption Feeds the Addiction Cycle and What You Can Do About It
Addiction Recovery Mental Health Wellness
November 6, 2026

You Might also Like

Three Biggest Pharmaceutical Lawsuits of 2012: Psychiatric Drugs Focus of All Three

August 8, 2012
good dental health
Dental health

The Importance of Dental Health: Tips and Tricks for a Beautiful Smile

April 13, 2023
end to end testing
Hospital Administration

End-to-End ICD-10 Testing: Are You Prepared?

March 3, 2014
Specialties

New Indication for Colonoscopy: High Value Target Captured.

May 6, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?